# OnCo record i-spy-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/i-spy-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "i-spy-1" ;
  schema:name "I-SPY 1 (CALGB 150007/150012, ACRIN 6657)"@en ;
  schema:alternateName "I-SPY 1 TRIAL"@en, "ISPY1"@en ;
  schema:description "I-SPY 1 followed women having chemotherapy before breast surgery with repeated MRI scans and biopsies, and showed that a tumour vanishing completely (a pathological complete response) predicted long-term survival, especially in the aggressive subtypes."@en ;
  schema:url <https://onco.cc/trials/i-spy-1/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://www.ispytrials.org/i-spy-platform/i-spy1>, <https://ascopubs.org/doi/10.1200/JCO.2011.39.2779> ;
  onco:status "completed" ;
  onco:phase "observational" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/gene-expression-prognostic-assays/> ;
  onco:drugs <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/alliance-oncology/>, <https://onco.cc/companies/ecog-acrin/> ;
  onco:institutions <https://onco.cc/institutions/ucsf/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/master-protocol/> ;
  onco:people <https://onco.cc/people/laura-esserman/> .